Bayer further invests in Singapore oncology alliances
Bayer HealthCare Singapore, a subsidiary of Germany-based Bayer, has added an additional SGD $14.5 million ($11.1 million U.S.) worth of investment that will go into enhancing its expertise in qualifying research and development activities in Singapore to improve early diagnosis and treatment outcomes of cancer patients.
In partnership with the National University of Singapore, National University Health System, SingHealth and Singapore Bioimaging Consortium, Bayer HealthCare will launch five new projects to investigate novel approaches to diagnose and treat cancers.
The partnership will help to accelerate Bayer HealthCare’s drug discovery and development in Asia. The collaboration is also part of Bayer HealthCare’s SGD $20 million ($15.3 million U.S.) investment in joint research projects with Singapore based universities, hospitals, research institutes and companies over six years.
Ludger Dinkelborg, PhD, head of therapeutic research group diagnostic imaging, Bayer HealthCare said: “We have only recently begun to understand the molecular basis of tumor-specific intermediary metabolism. Addressing these specific pathways with imaging technologies such as PET or MRI might help to diagnose cancer earlier and to better characterise the disease, leading to a better therapeutic outcome for our patients.”
In partnership with the National University of Singapore, National University Health System, SingHealth and Singapore Bioimaging Consortium, Bayer HealthCare will launch five new projects to investigate novel approaches to diagnose and treat cancers.
The partnership will help to accelerate Bayer HealthCare’s drug discovery and development in Asia. The collaboration is also part of Bayer HealthCare’s SGD $20 million ($15.3 million U.S.) investment in joint research projects with Singapore based universities, hospitals, research institutes and companies over six years.
Ludger Dinkelborg, PhD, head of therapeutic research group diagnostic imaging, Bayer HealthCare said: “We have only recently begun to understand the molecular basis of tumor-specific intermediary metabolism. Addressing these specific pathways with imaging technologies such as PET or MRI might help to diagnose cancer earlier and to better characterise the disease, leading to a better therapeutic outcome for our patients.”